[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534619":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":59,"collaborators":32,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":32,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":32,"enrollmentInfo":71,"targetDuration":32,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Stony Brook University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous Famotidine","ACTIVE_COMPARATOR","Patients in this group will receive 20 mg of intravenous famotidine.",[13],"Drug: Intravenous Famotidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Oral Maalox","Patients in the group will receive 30 ml of oral Maalox\u002F Mylanta.",[18],"Drug: Oral Maalox\u002F Mylanta",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Patients in this group will receive 20mg IV Famotidine.",[9],[25],"H2 Receptor Antagonist",{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Oral Maalox\u002F Mylanta","Patients in this group will receive 30 ml Maalox\u002F Mylanta.",[15],[31],"Antacid",null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Adam Singer, MD","CONTACT","6314447857","adam.singer@stonybrookmedicine.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Stony Brook University Hospital","RECRUITING","Stony Brook","New York","11794","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-73.14094,40.92565,{"lat":52,"lon":51},[55,57],{"name":56,"role":36,"phone":32,"phoneExt":32,"email":32},"Andrea Gowie",{"name":35,"role":58,"phone":32,"phoneExt":32,"email":32},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Adam Singer","Professor and Interim Chair of the Department of Emergency Medicine","100534619","phase-4-famotidine-and-antacids-for-treatment-of-dyspepsia-100534619",false,"NCT06241183","Famotidine and Antacids for Treatment of Dyspepsia","Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department","Inclusion Criteria:\n\n1. Subject Age ≥ 18 years of age\n2. Patient diagnosed with dyspepsia\n3. Present at the ED with upper abdominal pain score of at least 3\n\nExclusion Criteria:\n\n1. Hypersensitivity to an ingredient in Maalox\u002F Mylanta or Famotidine\n2. Moderate to Severe Renal Insufficiency (precaution)\n3. Kidney Failure\n4. Pregnant or Nursing\n5. Verbal pain score less than 3\n6. Inability to tolerate oral medications\n7. Bowel Obstruction\n8. Proton pump inhibitor within 2 hours of study treatment","ALL","18 Years",{"count":72,"type":73},80,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox\u002F Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.",[79,80,81],"Dyspepsia","GERD","Acid Reflux",[83,80,81,84,85,86,87,88],"dyspepsia","H2 receptor antagonist","antacid","Maalox","Mylanta","Famotidine","2026-06-01",{"date":91,"type":92},"2026-06-02","ACTUAL",{"date":94,"type":92},"2023-11-09",{"date":96,"type":73},"2027-12-31",{"name":5,"class":6},1]